55 related articles for article (PubMed ID: 1515095)
21. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Townsley CA; Chi K; Ernst DS; Belanger K; Tannock I; Bjarnason GA; Stewart D; Goel R; Ruether JD; Siu LL; Jolivet J; McIntosh L; Seymour L; Moore MJ;
J Clin Oncol; 2003 Apr; 21(8):1524-9. PubMed ID: 12697876
[TBL] [Abstract][Full Text] [Related]
22. Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma.
Sahasrabudhe DM; deKernion JB; Pontes JE; Ryan DM; O'Donnell RW; Marquis DM; Mudholkar GS; McCune CS
J Biol Response Mod; 1986 Dec; 5(6):581-94. PubMed ID: 3491881
[TBL] [Abstract][Full Text] [Related]
23. [Immunological assessment after radical nephrectomy for renal cell carcinomas pre-treated with interferon-gamma].
Onishi T; Machida T; Masuda F; Igarashi H
Hinyokika Kiyo; 1991 Jul; 37(7):671-8. PubMed ID: 1927765
[TBL] [Abstract][Full Text] [Related]
24. Immune modulating effects of low doses of cyclophosphamide and keyhole limpet hemocyanin on peripheral blood immune parameters in patients with metastatic renal cell carcinoma.
Kleinknecht S; Bichler KH; Strohmaier WL
Urol Int; 1992; 48(1):1-8. PubMed ID: 1598724
[TBL] [Abstract][Full Text] [Related]
25. Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination.
Slavc I; Schuller E; Czech T; Hainfellner JA; Seidl R; Dieckmann K
J Neurooncol; 1998; 38(2-3):213-8. PubMed ID: 9696374
[TBL] [Abstract][Full Text] [Related]
26. Phase-I study of mafosfamide-cyclohexylamine (ASTA-Z-7557, NSC 345 842) and limited phase-I data on mafosfamide-lysine.
Bruntsch U; Groos G; Hiller TA; Wandt H; Tigges FJ; Gallmeier WM
Invest New Drugs; 1985; 3(3):293-6. PubMed ID: 4066222
[TBL] [Abstract][Full Text] [Related]
27. Sensitivity of primary clonogenic blasts from acute lymphoblastic leukemia patients to an activated cyclophosphamide, viz., mafosfamide.
Uckun FM; Chandan-Langlie M; Dockham PA; Aeppli D; Sladek NE
Leuk Lymphoma; 1994 May; 13(5-6):417-28. PubMed ID: 8069187
[TBL] [Abstract][Full Text] [Related]
28. Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors.
Slavc I; Schuller E; Falger J; Günes M; Pillwein K; Czech T; Dietrich W; Rössler K; Dieckmann K; Prayer D; Hainfellner J
J Neurooncol; 2003 Sep; 64(3):239-47. PubMed ID: 14558599
[TBL] [Abstract][Full Text] [Related]
29. Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models.
Reissmann T; Voegeli R; Pohl J; Hilgard P
Cancer Immunol Immunother; 1989; 28(3):179-84. PubMed ID: 2924329
[TBL] [Abstract][Full Text] [Related]
30. Postoperative long-term course of peripheral blood immune parameters and immunomodulating effects of keyhole limpet hemocyanin in patients with nonmetastatic renal cell carcinoma.
Kleinknecht S; Bichler KH; Strohmaier WL
Eur Urol; 1992; 21(4):315-22. PubMed ID: 1459154
[TBL] [Abstract][Full Text] [Related]
31. Influence of low doses of an oxazaphosphorine on natural killer activity of human lymphocytes.
Blomgren H
Cancer Immunol Immunother; 1989; 29(2):151-3. PubMed ID: 2720708
[TBL] [Abstract][Full Text] [Related]
32. Mafosfamide as a new anticancer agent: preclinical investigations and clinical trials.
Mazur L; Opydo-Chanek M; Stojak M; Wojcieszek K
Anticancer Res; 2012 Jul; 32(7):2783-9. PubMed ID: 22753738
[TBL] [Abstract][Full Text] [Related]
33. Phase I study of cyclohexylamine and lysine salt of mafosfamide.
Abele R; Aapro MS; Haefliger JM; Alberto P
Cancer Chemother Pharmacol; 1986; 16(2):182-3. PubMed ID: 3512115
[TBL] [Abstract][Full Text] [Related]
34. N3-methyl-mafosfamide as a chemically stable, alternative prodrug of mafosfamide.
Moon KY; Kwon CH
Bioorg Med Chem Lett; 1998 Jul; 8(13):1673-8. PubMed ID: 9873412
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of MVE-2 evaluating toxicity and biologic response modification capability.
Hainsworth JD; Forbes JT; Grosh WW; Greco FA
Cancer Immunol Immunother; 1986; 22(1):68-71. PubMed ID: 2423241
[TBL] [Abstract][Full Text] [Related]
36. Activation mechanisms of mafosfamide and the role of thiols in cyclophosphamide metabolism.
Kwon CH; Borch RF; Engel J; Niemeyer U
J Med Chem; 1987 Feb; 30(2):395-9. PubMed ID: 3806619
[TBL] [Abstract][Full Text] [Related]
37. Regional fibrosis after intraperitoneal administration of mafosfamide.
Roberts JD; Newman RA; Kimberly PJ; Hacker MP
Invest New Drugs; 1986; 4(1):61-5. PubMed ID: 2939038
[TBL] [Abstract][Full Text] [Related]
38. Antitumoral activity of the oxazaphosphorine derivative, mafosfamide-cyclohexylamine salt (ASTA 7557) on a murine ovarian reticular cell sarcoma and its subline resistant to cyclophosphamide.
Colombo T; Paolini A; Finazzi M; Scanziani E; Mandelli G; Donelli MG
Tumori; 1986 Dec; 72(6):637-42. PubMed ID: 3544404
[TBL] [Abstract][Full Text] [Related]
39. A phase I study of immunostimulation and toxicity in patients with colorectal carcinoma using the immunomodulator 3,6-bis(2-piperidinoethoxy) acridine trihydrochloride (CL 246738).
Lennard TW; Harris AL; Hales J; Dickinson A; Wolstencroft R; Halcrow P; Shenton BK; McDonald M; Lawrence GF; Taylor RM
Eur J Cancer Clin Oncol; 1989 Nov; 25(11):1571-6. PubMed ID: 2591449
[TBL] [Abstract][Full Text] [Related]
40. Metabolism and pharmacokinetics of oxazaphosphorines.
Boddy AV; Yule SM
Clin Pharmacokinet; 2000 Apr; 38(4):291-304. PubMed ID: 10803453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
